The therapeutic landscape for brain metastases in EGFR and ALK-mutated non-small cell lung cancer has been fundamentally transformed by the advent and evolution of tyrosine kinase inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.